PMA patent complaint v. Korea
Executive Summary
PMA President Mossinghoff is asking the Commerce Department via a March 10 letter "to send an appropriate signal to Korea" for what the association called deviations from a bilateral U.S.-South Korean agreement. "For the past year," the association maintained, "the Korean government has sought to renegotiate the agreement it signed in order to inhibit the sale of U.S. patented products in that country." PMA charged that Korea is not protecting drug product or process patents and is not enforcing its pre-agreement patent laws.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.